Cargando…

Effects of riociguat in severe experimental pulmonary hypertension

Detalles Bibliográficos
Autores principales:	Kojonazarov, Baktybek, Lang, Michaela, Weissmann, Norbert, Grimminger, Friedrich, Stasch, Johannes-Peter, Seeger, Werner, Ghofrani, Hossein Ardeschir, Schermuly, Ralph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363233/ http://dx.doi.org/10.1186/1471-2210-11-S1-P39

Ejemplares similares

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

Reply to Bogaard et al.: Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2019)

Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding
por: Rai, Nabham, et al.
Publicado: (2018)

Response to: Comment on “Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding”
por: Rai, Nabham, et al.
Publicado: (2018)

Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension
por: Veeroju, Swathi, et al.
Publicado: (2021)

sGC activators and stimulators attenuate ischemia/reperfusion injury of the lung
por: Egemnazarov, Bakytbek, et al.
Publicado: (2009)

Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension
por: Amirjanians, Matthieu, et al.
Publicado: (2017)

IRAG1 Deficient Mice Develop PKG1β Dependent Pulmonary Hypertension
por: Biswas, Siladitta, et al.
Publicado: (2020)

Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors
por: Schermuly, Ralph Theo, et al.
Publicado: (2005)

Improvement of right heart structure and function by BAY 41-8543 in pulmonary artery banded mice
por: Janssen, Wiebke, et al.
Publicado: (2011)

Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension
por: Rai, Nabham, et al.
Publicado: (2022)

Effects of Multikinase inhibitors on pressure overload-induced right ventricular remodelling
por: Kojonazarov, Baktybek, et al.
Publicado: (2013)

A novel noninvasive method for estimating right ventricular systolic pressure in rodents with pulmonary artery banding
por: Kojonazarov, Baktybek, et al.
Publicado: (2023)

Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice
por: Seimetz, Michael, et al.
Publicado: (2015)

Genetic Deficiency and Pharmacological Stabilization of Mast Cells Ameliorate Pressure Overload-Induced Maladaptive Right Ventricular Remodeling in Mice
por: Sydykov, Akylbek, et al.
Publicado: (2020)

Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
por: Weiss, Astrid, et al.
Publicado: (2019)

Retraction: Nitric Oxide Synthase 2 Induction Promotes Right Ventricular Fibrosis
por: Boehm, Mario, et al.
Publicado: (2022)

Correction: Improvement of right heart structure and function by BAY41-8543 in pulmonary artery banded mice
por: Janssen, Wiebke, et al.
Publicado: (2011)

Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension
por: Kosanovic, Djuro, et al.
Publicado: (2011)

Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension
por: Boehm, Mario, et al.
Publicado: (2018)

Correction to: Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension
por: Boehm, Mario, et al.
Publicado: (2022)

Glycogen Synthase Kinase 3beta Contributes to Proliferation of Arterial Smooth Muscle Cells in Pulmonary Hypertension
por: Sklepkiewicz, Piotr, et al.
Publicado: (2011)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
por: Mamazhakypov, Argen, et al.
Publicado: (2020)

Phosphodiesterase 10A Upregulation Contributes to Pulmonary Vascular Remodeling
por: Tian, Xia, et al.
Publicado: (2011)

Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration
por: Pullamsetti, Soni, et al.
Publicado: (2005)

Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-β
por: Dahal, Bhola K., et al.
Publicado: (2011)

Genes involved in pulmonary hypertension of mice with endothelial-specific ablation of guanylyl cyclase A
por: Werner, Franziska, et al.
Publicado: (2013)

Cardio-renal protection of riociguat (BAY 63-2521) in low- and high-renin models of hypertension
por: Kalk, Philipp, et al.
Publicado: (2009)

Correction to: Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice
por: Udalov, Sergey, et al.
Publicado: (2022)

Diacylglycerol regulates acute hypoxic pulmonary vasoconstriction via TRPC6
por: Fuchs, Beate, et al.
Publicado: (2011)

Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2
por: Novoyatleva, Tatyana, et al.
Publicado: (2021)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Author Correction: Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2
por: Novoyatleva, Tatyana, et al.
Publicado: (2022)

5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure
por: Janssen, Wiebke, et al.
Publicado: (2015)

Decreased plasma levels of the brain-derived neurotrophic factor correlate with right heart congestion in pulmonary arterial hypertension
por: Schäfer, Katharina, et al.
Publicado: (2023)

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
por: Mittendorf, Joachim, et al.
Publicado: (2009)

Myeloid-cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice
por: Gredic, Marija, et al.
Publicado: (2022)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8hbkhf3ar0usfg266uhlfbtmlt